Aktis Oncology, Inc.
Aktis Oncology (NASDAQ:AKTS) began a Phase 1b trial for AKY-2519 in lung cancer and other solid tumors. The multicenter study will test three dose levels. The company also has ongoing trials for prostate cancer and Nectin-4 expressing tumors, with data expected in 2027. Aktis develops targeted radioconjugates and collaborates with Eli Lilly.
Analysts made several rating changes: TD Cowen initiated Faeth Therapeutics as buy, Barclays upgraded Sagimet Biosciences to overweight, JPMorgan upgraded Lithium Americas to overweight, and more. Price targets were also adjusted for companies like Affirm, Robinhood, and First Solar.
Bank of America cited a July selloff in AI stocks and named 16 “oversold” picks it rates Buy and Top Pick, each down at least 20% from 52-week highs. Examples include Oracle (ORCL) down 55% and CoreWeave (CRWV) down 31%. BofA also listed 12-month price targets, including MU $1,550 (+63%) and ORCL $240 (+54%).
Over the past 7 days, AlphAI's AI scored 1 news story mentioning AKTS (Aktis Oncology, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent AKTS coverage spans financial news, insider activity and sector analysis.
In the last 30 days, AKTS insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($259K). The most active reporter was Czibere Akos, Chief Medical Officer, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The trial start adds a new catalyst that could lift the stock if early data are positive.
Positive rating may support stock.
AKTS is presented as part of the oversold list without a specific new catalyst in the article.
The inclusion suggests BofA sees upside from earnings revisions and valuation, but the article does not connect it to a new AI-specific development.
The filing updates Aktis’ funding runway and advances multiple actinium-225 miniprotein programs, which can shift near-term risk perception and biotech financing expectations.
AlphAI scores every news story that mentions AKTS with an AI model for sentiment and relevance, and aggregates insider trades from Aktis Oncology, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Aktis Oncology (NASDAQ:AKTS) began a Phase 1b trial for AKY-2519 in lung cancer and other solid tumors. The multicenter study will test three dose levels. The company also has ongoing trials for prostate cancer and Nectin-4 expressing tumors, with data expected in 2027. Aktis develops targeted radioconjugates and collaborates with Eli Lilly.
2 min readAnalysts made several rating changes: TD Cowen initiated Faeth Therapeutics as buy, Barclays upgraded Sagimet Biosciences to overweight, JPMorgan upgraded Lithium Americas to overweight, and more. Price targets were also adjusted for companies like Affirm, Robinhood, and First Solar.
3 min readBank of America cited a July selloff in AI stocks and named 16 “oversold” picks it rates Buy and Top Pick, each down at least 20% from 52-week highs. Examples include Oracle (ORCL) down 55% and CoreWeave (CRWV) down 31%. BofA also listed 12-month price targets, including MU $1,550 (+63%) and ORCL $240 (+54%).
7 min readBank of America said its AI-infrastructure stock screen found 16 Buy-rated names trading more than 20% below 52-week highs, with positive three-month earnings revisions. Micron (MU) had the largest implied upside versus BofA’s $1,550 target, about 63%. BofA cited server DRAM pricing growth and tight supply, plus long-term 2028 EPS estimate near $150.
5 min readAktis Oncology, Inc. (AKTS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026 • Presented first-in-human clinical imaging and dosimetry data for AKY-2519, supporting a broad clinical development program in patients with prostate, lung, and other B7-H3 expressing so
6 min readHerrmann Ken sold 4,856 shares of Aktis Oncology, Inc. (AKTS) at $24.56 ($0.12M total) across 2 trades on 2026-07-20.
1 min readRon-Bigger Shulamit (Chief Operating Officer) sold 50,000 shares of Aktis Oncology, Inc. (AKTS) at an average of $27.75 ($27.13–$28.75, $1.39M total) across 3 trades on 2026-07-08.
1 min readCzibere Akos (Chief Medical Officer) sold 50,000 shares of Aktis Oncology, Inc. (AKTS) at an average of $27.77 ($27.13–$28.71, $1.39M total) across 3 trades on 2026-07-08.
2 min readThe article highlights five healthcare stocks that insiders are actively buying, indicating potential confidence in their future performance. It specifically details Aktis Oncology (NASDAQ:AKTS) as one such company, noting a raised price target from an analyst and recent FDA clearance for a Phase 1b trial of its investigational miniprotein radioconjugate. The piece also includes an extended advertisement for an AI stock, separate from the healthcare stock analysis.
3 min readAktis Oncology announced that the FDA cleared Investigational New Drug (IND) applications for AKY-2519, a miniprotein radioconjugate targeting B7-H3, enabling a Phase 1b clinical trial to begin in mid-2026. The company also provided business updates, including the Fast Track designation for its lead candidate AKY-1189, and reported financial results for 2025, showing increased R&D expenses and a net loss of $63.7 million. With a pro forma cash position of $562.1 million after its January 2026 IPO, Aktis anticipates funding operations into 2029.
4 min read
